•  
  •  
 

Subject Area

Dermatology

Article Type

Original Study

Abstract

Objectives: To measure the level of YKL-40 in COVID-19 patients with and without skin lesion in Elbagour Hospital.

Background: The outbreak of coronavirus disease 2019 (COVID-19), caused by

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, has

emerged in China in December 2019 and rapidly spread to more than 196 countries worldwide.

Methods: A case-control study was conducted on a total number of 180 patients

including 60 COVID -19 patients with skin manifestations and 60 COVID- 19 patients without skin manifestations besides 60 age and gender-matched healthy subjects as a control group. The patients were those attending El-Bagour Hospital COVID- 19 isolation from March 2020 to March 2021. Diagnosis of COVID-19 was done clinically and by laboratory investigations, confirmed by PCR.

Results: The mean levels of YKL-40 were significantly higher in COVID-19 patients than in the controls (66.47 ± 66.52 ng/ml vs 17.25 ± 3.16 ng/ml). The mean levels of YKL-40 were significantly higher in COVID-19 patients with cutaneous

manifestations than those without cutaneous manifestations (94.85 ± 84.50 ng/ml vs 38.09 ± 12.12 ng/ml).

Conclusion: The mean level of YKL-40 was significantly higher in COVID-19

patients especially severe cases than the controls and in COVID-19 patients with

cutaneous manifestations than those without cutaneous manifestations.

Download

Share

COinS